There has been considerable interest in studying novel biomarkers in chronic kidney disease (CKD) beyond the conventional clinical indices, such as serum creatinine, blood urea nitrogen, and urine protein or urine albumin. The motivation for this is similar to what has been outlined in other articles in this issue of ASN Kidney News. For example, novel biomarkers may improve our ability to better risk classify patients and guide clinical actions (e.g., closer follow-up and more intense treatment for patients at higher risk of progression of CKD), to identify high-risk patients for enrollment into clinical trials (as enriched enrollment of patients who are more likely to progress will enhance study power), and to better understand underlying biological pathophysiological mechanisms (which may in turn identify novel targets for treatment).
Under the sponsorship of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a CKD Biomarker Consortium was formed in 2009. The consortium consists of investigators from more than a dozen academic medical centers and research institutions around the country, analyzing clinical data and stored biosamples and from numerous longitudinal cohorts.
Dr. Hsu is a member of the CKD Biomarker Consortium. Abbott had donated urine biomarker assays (NGAL) to the CKD Biomarker Consortium. Dr. Bansal is supported by K23 DK88865; Dr. Hsu by U01 DK85649 and K24 DK92291.
Liu KD, et al.. Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int 2013; 83:909–914.
Fufaa GD, et al.. Association of urinary KIM-1, L-FABP, NAG, and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus [Abstract]. J Am Soc Nephrol 2013; 24:427A.
Bolignano D, et al.. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:337–344.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296–1305.
Gerstein HC, et al.. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421–426.
Driver TH, et al.. Urinary Kidney Injury Molecule 1 (KIM-1) and Interleukin 18 (IL-18) as risk markers for heart failure in older adults: The Health, Aging, and Body Composition (Health ABC) Study. Am J Kidney Dis. doi: 10.1053/j.ajkd.2014.01.432.
Sarnak MJ, et al.. Association of urinary injury biomarkers with mortality and cardiovascular events. J Am Soc Nephrol. doi:10.1681/ASN.2013070713.
Peralta C, et al.. Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women’s Interagency HIV Study (WIHS). HIV Med. doi: 10.1111/hiv.12113.
Shlipak MG, et al.. Urinary markers of kidney injury and kidney function decline in HIV-infected women. J Acquir Immune Defic Syndr 2012; 61:565–573.
Oboho I, et al.. Tenofovir use and urinary biomarkers among HIV-infected women in the Women’s Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2013; 62:388–395.
Hall AM, et al.. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis 2009; 54:1034–1042.